BioHarvest Sciences will release its third‑quarter 2025 earnings on Thursday, November 13, 2025, following the market close.
The company will host an investor conference call and webcast at 4:30 p.m. Eastern time on November 13. Participants can dial in at 1‑877‑300‑8521 (U.S./Canada) or 1‑412‑317‑6026 (international) using conference ID 6486821. A telephone playback will be available on November 27, 2025, and a webcast replay will also be posted.
Preliminary unaudited guidance for the quarter indicates revenue of approximately $9.1 million and adjusted EBITDA between ($0.7 million) and ($0.4 million). Cash and cash equivalents as of September 30, 2025, were about $11 million.
The company’s revenue growth is driven by its VINIA® product line, which accounted for roughly 80 % of revenue, with new VINIA products contributing about 20 %. The CDMO services division also contributed to revenue, supporting the company’s dual‑vertical strategy.
Management highlighted continued investment in marketing and development of the VINIA® BloodFlow Hydration product, as well as the launch of a strategic CDMO agreement with Saffron Tech on October 30, 2025, to develop saffron‑derived botanical compounds.
For the fourth quarter of 2025, the company projects revenue of $9 million to $9.5 million and adjusted EBITDA of ($0.6 million) to $0. The earnings release and related materials will be posted on BioHarvest’s investor relations website.
The earnings release covers the period ended September 30, 2025.
In comparison, the company reported revenue of $8.5 million and a net loss of $4.0 million for the second quarter of 2025, and $6.5 million and a net loss of $2.7 million for the third quarter of 2024.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.